Table 2.
Changes in the disease activity evaluation index, serological index and glucocorticoid dose after 4, 12, 24 and 52 weeks of treatment with telitacicept
| Baseline (n=72) |
4 weeks (n=72) |
12 weeks (n=72) |
24 weeks (n=72) |
52 weeks (n=21) |
|
| Disease activity | |||||
| SRI-4, n (%) | – | 16 (22.22) | 39 (54.17) | 52 (72.22) | 17 (80.95) |
| LLDAS, n (%) | – | 6 (8.33) | 19 (26.39) | 25 (34.72) | 10 (47.62) |
| Remission, n (%) | – | 0 (0) | 3 (4.17) | 6 (8.33) | 5 (23.81) |
| Serological index | |||||
| IgA, g/L (mean±SD) | 2.42±0.94 | 2.01±0.88 | 1.90±0.89 | 1.82±0.75 | 1.85±0.71 |
| IgG, g/L (mean±SD) | 13.17±6.49 | 10.84±5.32 | 10.68±5.77 | 10.94±6.22 | 9.99±5.13 |
| IgM, g/L (mean±SD) | 1.06±0.70 | 0.80±0.49 | 0.72±0.56 | 0.64±0.36 | 0.60±0.36 |
| Normal C3, n (%) | 14 (19.44) | 26 (36.11) | 31 (43.05) | 35 (48.61) | 16 (76.19) |
| Normal C4, n (%) | 13 (18.05) | 26 (36.11) | 38 (52.78) | 42 (58.33) | 21 (100.00) |
| Glucocorticoid (GC) dosage | |||||
| GC ≤10 mg, n (%) | 33 (45.8) | 39 (54.2) | 50 (69.4) | 64 (88.9) | 21 (100.0) |
| 10 mg<GC<30 mg, n (%) |
13 (18.1) | 17 (23.6) | 21 (29.2) | 8 (11.1) | 0 (0.00) |
| GC ≥30 mg, n (%) | 26 (36.1) | 16 (22.2) | 1 (1.4) | 0 (0.0) | 0 (0.00) |
| Mean±SD, mg | 19.15±14.52 | 16.32±10.64 | 11.25±5.19 | 8.99±3.24 | 8.21±2.11 |
LLDAS, Lupus Low Disease Activity State; SRI-4, SLE Responder Index 4.